Immune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours

Project Information

IMPACT

Grant agreement ID: 101188848

DOI

10.3030/101188848

EC signature date 30 November 2024

Start date 1 December 2024

End date 30 November 2026

Funded under

• The European Innovation Council (EIC)

Total cost

No data

EU contribution

€ 2 498 730,50

Coordinated by

IMPACT BIOTECH LTD
Israel

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

ENLIGHTED phase 3 study: Interim results of efficacy and safety of padeliporfin vascular targeted photodynamic therapy (VTP) in the treatment of low-grade upper tract urothelial cancer (LG UTUC).

Author(s): Vitaly Margulis, Ronald P. Kaufman, Gautier Marcq, Asaf Shvero, Neal D. Shore, Sarah P. Psutka, Edward M. Uchio, Hooman Djaladat, Jay D. Raman, Ahmad Shabsigh, Marc Colombel, Marcos Aller, Steffen Rau
Published in: Journal of Clinical Oncology, Issue 43, 2025, ISSN 0732-183X
Publisher: American Society of Clinical Oncology (ASCO)
DOI: 10.1200/JCO.2025.43.17_SUPPL.LBA4513

EFFICACY AND SAFETY OF PADELIPORFIN VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR TREATMENT OF LOW-GRADE UPPER TRACT UROTHELIAL CANCER (LG UTUC): ENLIGHTED PHASE 3 STUDY

Author(s): Vitaly Margulis, Ronald P Kaufman Jr, Gautier Marcq, Neal Shore, Asaf Shvero, Sarah Psutka, Edward Edward Uchio, Hooman Djaladat, Jay Raman, Marc Colombel, Marcos Aller, Steffen Rausch, Aigner Reinhar
Published in: Urologic Oncology: Seminars and Original Investigations, Issue 43, 2025, ISSN 1078-1439
Publisher: Elsevier BV
DOI: 10.1016/J.UROLONC.2024.12.243